Paradoxical Suppression of Atherosclerosis in the Absence of microRNA-146a.

Cheng, Henry S; Besla, Rickvinder; Li, Angela; Chen, Zhiqi; Shikatani, Eric A; Nazari-Jahantigh, Maliheh; Hammoutène, Adel; Nguyen, My-Anh et al. · Circ Res · 2017

basic_science · Level V

Where this comes from

Abstract

Inflammation is a key contributor to atherosclerosis. MicroRNA-146a (miR-146a) has been identified as a critical brake on proinflammatory nuclear factor κ light chain enhancer of activated B cells signaling in several cell types, including endothelial cells and bone marrow (BM)-derived cells. Importantly, miR-146a expression is elevated in human atherosclerotic plaques, and polymorphisms in the <i>miR-146a</i> precursor have been associated with risk of coronary artery disease. To define the role of endogenous miR-146a during atherogenesis. Paradoxically, <i>Ldlr</i><sup>-/-</sup> (low-density lipoprotein receptor null) mice deficient in <i>miR-146a</i> develop less atherosclerosis, despite having highly elevated levels of circulating proinflammatory cytokines. In contrast, cytokine levels are normalized in <i>Ldlr</i><sup>-/-</sup><i>;miR-146a</i><sup>-/-</sup> mice receiving wild-type BM transplantation, and these mice have enhanced endothelial cell activation and elevated atherosclerotic plaque burden compared with <i>Ldlr</i><sup>-/-</sup> mice receiving wild-type BM, demonstrating the atheroprotective role of miR-146a in the endothelium. We find that deficiency of <i>miR-146a</i> in BM-derived cells precipitates defects in hematopoietic stem cell function, contributing to extramedullary hematopoiesis, splenomegaly, BM failure, and decreased levels of circulating proatherogenic cells in mice fed an atherogenic diet. These hematopoietic phenotypes seem to be driven by unrestrained inflammatory signaling that leads to the expansion and eventual exhaustion of hematopoietic cells, and this occurs in the face of lower levels of circulating low-density lipoprotein cholesterol in mice lacking <i>miR-146a</i> in BM-derived cells. Furthermore, we identify sortilin-1(<i>Sort1</i>), a known regulator of circulating low-density lipoprotein levels in humans, as a novel target of miR-146a. Our study reveals that miR-146a regulates cholesterol metabolism and tempers chronic inflammatory responses to atherogenic diet by restraining proinflammatory signaling in endothelial cells and BM-derived cells.

Medical subject headings